Home › Compare › NWDVW vs ABBV

NWDVW vs ABBV: Dividend Comparison 2026

NWDVW yields 40000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NWDVW wins by $5.18024517379999e+22M in total portfolio value
10 years
NWDVW
NWDVW
● Live price
40000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.18024517379999e+22M
Annual income
$51,548,940,318,215,365,000,000,000,000.00
Full NWDVW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NWDVW vs ABBV

📍 NWDVW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNWDVWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NWDVW + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NWDVW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NWDVW
Annual income on $10K today (after 15% tax)
$3,400,000.00/yr
After 10yr DRIP, annual income (after tax)
$43,816,599,270,483,060,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NWDVW beats the other by $43,816,599,270,483,060,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NWDVW + ABBV for your $10,000?

NWDVW: 50%ABBV: 50%
100% ABBV50/50100% NWDVW
Portfolio after 10yr
$2.590122586899995e+22M
Annual income
$25,774,470,159,107,683,000,000,000,000.00/yr
Blended yield
99.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NWDVW
No analyst data
Altman Z
0.5
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NWDVW buys
0
ABBV buys
0
No recent congressional trades found for NWDVW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNWDVWABBV
Forward yield40000.00% ✓3.06%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$5.18024517379999e+22M$102.3K ✓
Annual income after 10y$51,548,940,318,215,365,000,000,000,000.00 ✓$24,771.77
Total dividends collected$5.178579568047658e+22M$61.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NWDVW vs ABBV ($10,000, DRIP)

YearNWDVW PortfolioNWDVW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$4,010,700$4,000,000.00$11,550$430.00+$4.00M → NWDVW
2$1,503,618,552$1,499,327,102.80$13,472$627.96+$1503.61M → NWDVW
3$526,936,342,129$525,327,470,278.19$15,906$926.08+$526936.33M → NWDVW
4$172,618,628,820,566$172,054,806,934,488.28$19,071$1,382.55+$172618628.80M → NWDVW
5$52,860,672,107,805,460$52,675,970,174,967,450.00$23,302$2,095.81+$52860672107.78M → NWDVW
6$15,132,132,379,588,594,000$15,075,571,460,433,242,000.00$29,150$3,237.93+$15132132379588.56M → NWDVW
7$4,049,462,878,006,525,600,000$4,033,271,496,360,366,000,000.00$37,536$5,121.41+$4049462878006525.50M → NWDVW
8$1,013,053,710,099,385,500,000,000$1,008,720,784,819,918,400,000,000.00$50,079$8,338.38+$1013053710099385472.00M → NWDVW
9$236,926,560,546,299,530,000,000,000$235,842,593,076,493,200,000,000,000.00$69,753$14,065.80+$236926560546299510784.00M → NWDVW
10$51,802,451,737,999,890,000,000,000,000$51,548,940,318,215,365,000,000,000,000.00$102,337$24,771.77+$5.18024517379999e+22M → NWDVW

NWDVW vs ABBV: Complete Analysis 2026

NWDVW — Stock

NWDVW is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NWDVW shares.

Full NWDVW Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NWDVW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NWDVW vs SCHDNWDVW vs JEPINWDVW vs ONWDVW vs KONWDVW vs MAINNWDVW vs JNJNWDVW vs MRKNWDVW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.